drugset / Trial / NCT04923347
A Study to Evaluate the Safety and Efficacy of Fluticasone Furoate (FF)/Umeclidinium(UMEC)/Vilanterol (VI) in Participants With Chronic Obstructive Pulmonary Disease (COPD)
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate safety and efficacy of FF/UMEC/VI via ELLIPTA® inhaler. ELLIPTA is a registered trademark of GlaxoSmithKline group of companies.
Timeline
- Start
- 2023-06-06
- Primary completion
- 2024-03-14
- Completion
- 2024-03-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluticasone Furoate | Other / unclassified | — | Inhaled |
| Subject | Umeclidinium | Other / unclassified | — | Inhaled |
| Subject | Vilanterol | Other / unclassified | — | Inhaled |